JP2005525341A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005525341A5 JP2005525341A5 JP2003567874A JP2003567874A JP2005525341A5 JP 2005525341 A5 JP2005525341 A5 JP 2005525341A5 JP 2003567874 A JP2003567874 A JP 2003567874A JP 2003567874 A JP2003567874 A JP 2003567874A JP 2005525341 A5 JP2005525341 A5 JP 2005525341A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- optionally substituted
- alkoxy
- phenyl
- hydroxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 296
- 229910052736 halogen Inorganic materials 0.000 claims description 36
- 150000002367 halogens Chemical class 0.000 claims description 36
- 229910052739 hydrogen Inorganic materials 0.000 claims description 34
- 125000003545 alkoxy group Chemical group 0.000 claims description 33
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 32
- -1 nitro, hydroxy Chemical group 0.000 claims description 29
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 28
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 24
- 125000000623 heterocyclic group Chemical group 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 20
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 19
- 150000003839 salts Chemical class 0.000 claims description 17
- 125000001072 heteroaryl group Chemical group 0.000 claims description 16
- 239000012453 solvate Substances 0.000 claims description 16
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 12
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 125000003107 substituted aryl group Chemical group 0.000 claims description 9
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 8
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 8
- 125000004043 oxo group Chemical group O=* 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 4
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims description 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims description 4
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims description 4
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims description 4
- 150000001204 N-oxides Chemical class 0.000 claims description 4
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims description 4
- 125000005553 heteroaryloxy group Chemical group 0.000 claims description 4
- 229910052757 nitrogen Inorganic materials 0.000 claims description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229960005141 piperazine Drugs 0.000 claims description 4
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- 125000002757 morpholinyl group Chemical group 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 5
- 102000019034 Chemokines Human genes 0.000 claims 2
- 108010012236 Chemokines Proteins 0.000 claims 2
- 241000124008 Mammalia Species 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 claims 1
- QSDKXMVGRLVIQV-UHFFFAOYSA-N 1,2-dichloro-4-fluorobenzene Chemical compound FC1=CC=C(Cl)C(Cl)=C1 QSDKXMVGRLVIQV-UHFFFAOYSA-N 0.000 claims 1
- ROBKVGDBQLURAF-UHFFFAOYSA-N 1,4-dihydroquinoline Chemical compound C1=CC=C2CC=CNC2=C1 ROBKVGDBQLURAF-UHFFFAOYSA-N 0.000 claims 1
- WOHLSTOWRAOMSG-UHFFFAOYSA-N 2,3-dihydro-1,3-benzothiazole Chemical compound C1=CC=C2SCNC2=C1 WOHLSTOWRAOMSG-UHFFFAOYSA-N 0.000 claims 1
- GDSQTWDUCDSZEY-UHFFFAOYSA-N 4,5,6,7-tetrahydro-1h-indazole Chemical compound C1CCCC2=C1C=NN2 GDSQTWDUCDSZEY-UHFFFAOYSA-N 0.000 claims 1
- DQNSSLUVUXZLEO-UHFFFAOYSA-N 4-(3,4-dichlorophenoxy)piperidine Chemical compound C1=C(Cl)C(Cl)=CC=C1OC1CCNCC1 DQNSSLUVUXZLEO-UHFFFAOYSA-N 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- MXMZCLLIUQEKSN-UHFFFAOYSA-N benzimidazoline Chemical compound C1=CC=C2NCNC2=C1 MXMZCLLIUQEKSN-UHFFFAOYSA-N 0.000 claims 1
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 claims 1
- 239000003153 chemical reaction reagent Substances 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000000842 isoxazolyl group Chemical group 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 125000000335 thiazolyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0200465A SE0200465D0 (sv) | 2002-02-18 | 2002-02-18 | Chemical compounds |
| SE0202673A SE0202673D0 (sv) | 2002-09-09 | 2002-09-09 | Chemical compounds |
| PCT/SE2003/000258 WO2003068743A1 (en) | 2002-02-18 | 2003-02-17 | Chemical compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005525341A JP2005525341A (ja) | 2005-08-25 |
| JP2005525341A5 true JP2005525341A5 (https=) | 2006-04-13 |
| JP4435571B2 JP4435571B2 (ja) | 2010-03-17 |
Family
ID=27736686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003567874A Expired - Fee Related JP4435571B2 (ja) | 2002-02-18 | 2003-02-17 | 化学化合物 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US7709500B2 (https=) |
| EP (1) | EP1478624B1 (https=) |
| JP (1) | JP4435571B2 (https=) |
| KR (1) | KR20040084920A (https=) |
| CN (1) | CN100352807C (https=) |
| AR (1) | AR038566A1 (https=) |
| AT (1) | ATE480518T1 (https=) |
| AU (1) | AU2003206554B2 (https=) |
| BR (1) | BR0307477A (https=) |
| CA (1) | CA2472822A1 (https=) |
| CO (1) | CO5611135A2 (https=) |
| DE (1) | DE60334074D1 (https=) |
| IL (1) | IL195011A0 (https=) |
| IS (1) | IS7381A (https=) |
| MX (1) | MXPA04007906A (https=) |
| NO (1) | NO20043899L (https=) |
| NZ (1) | NZ534296A (https=) |
| PL (1) | PL372538A1 (https=) |
| RU (2) | RU2330019C2 (https=) |
| SG (1) | SG149695A1 (https=) |
| TW (1) | TW200303304A (https=) |
| WO (1) | WO2003068743A1 (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR028948A1 (es) | 2000-06-20 | 2003-05-28 | Astrazeneca Ab | Compuestos novedosos |
| TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| AU2003286711A1 (en) * | 2002-10-25 | 2004-05-13 | Vertex Pharmaceuticals Incorporated | Indazolinone compositions useful as kinase inhibitors |
| SE0400208D0 (sv) * | 2004-02-02 | 2004-02-02 | Astrazeneca Ab | Chemical compounds |
| EP1781637A1 (en) | 2004-06-29 | 2007-05-09 | Rigel Pharmaceuticals, Inc. | 2-substituted quinoline compounds and their uses as inhibitors of the ige receptor signaling cascade |
| JP3964417B2 (ja) | 2004-09-27 | 2007-08-22 | 国立大学法人金沢大学 | インドール誘導体を有効成分とするα２受容体遮断剤及び血管拡張剤 |
| SE0403003D0 (sv) * | 2004-12-09 | 2004-12-09 | Astrazeneca Ab | Chemical compound 1 |
| GT200500375A (es) * | 2004-12-20 | 2006-11-28 | Derivados de piperidina y su uso como agentes antiinflamatorios | |
| WO2007014054A2 (en) * | 2005-07-22 | 2007-02-01 | Glaxo Group Limted | Benzenesulfonamide inhibitor of ccr2 chemokine receptor |
| TW200734305A (en) * | 2005-08-02 | 2007-09-16 | Astrazeneca Ab | New salt III |
| TW200738634A (en) * | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
| TW200738635A (en) * | 2005-08-02 | 2007-10-16 | Astrazeneca Ab | New salt |
| CA2645551C (en) | 2006-03-16 | 2016-06-28 | Renovis, Inc. | Bicycloheteroaryl compounds as p2x7 modulators and uses thereof |
| TW200812582A (en) * | 2006-04-06 | 2008-03-16 | Astrazeneca Ab | Medicaments |
| JP2007297305A (ja) * | 2006-04-28 | 2007-11-15 | Daiso Co Ltd | Ｎ−（２，３−エポキシ−２−メチルプロピル）フタルイミドの製造法 |
| DE102006060598A1 (de) * | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | Tetrahydrobenzoisoxazole |
| US7968536B2 (en) * | 2007-06-29 | 2011-06-28 | Millennium Pharmaceuticals, Inc. | Heterocyclic compounds useful as RAF kinase inhibitors |
| JP5588167B2 (ja) * | 2009-12-28 | 2014-09-10 | ライオン株式会社 | 育毛養毛剤、毛周期変換剤および育毛養毛組成物 |
| JP5864546B2 (ja) | 2010-05-07 | 2016-02-17 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | インダゾール |
| BR112013030302B1 (pt) * | 2011-06-10 | 2021-08-24 | Chiesi Farmaceutici S.P.A. | Composto, composição farmacêutica, uso de um composto, combinação de um composto e dispositivo |
| US9394283B2 (en) * | 2012-04-13 | 2016-07-19 | Epizyme, Inc. | Salt form of a human histone methyltransferase EZH2 inhibitor |
| CN105164118A (zh) | 2013-05-08 | 2015-12-16 | 埃科特莱茵药品有限公司 | 抗菌性苯酞衍生物 |
| MA41140A (fr) * | 2014-12-12 | 2017-10-17 | Cancer Research Tech Ltd | Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg |
| MA41179A (fr) | 2014-12-19 | 2017-10-24 | Cancer Research Tech Ltd | Composés inhibiteurs de parg |
| CN107674013B (zh) * | 2016-08-02 | 2022-05-24 | 上海迪诺医药科技有限公司 | 多环化合物、其制备方法、药物组合物及应用 |
| EP4406609A3 (en) * | 2017-05-30 | 2024-10-02 | Day One Biopharmaceuticals, Inc. | Method for producing optically active compound |
| MX2024011545A (es) | 2022-03-23 | 2024-09-26 | Ideaya Biosciences Inc | Compuestos de indazol sustituidos con piperazina como inhibidores de parg. |
| KR102650222B1 (ko) | 2023-02-14 | 2024-03-21 | (주)오송 | 살균제용 조성물 및 이를 이용한 제품 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2676054B1 (fr) * | 1991-05-03 | 1993-09-03 | Sanofi Elf | Nouveaux composes n-alkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant. |
| IL118768A (en) * | 1995-07-12 | 2000-10-31 | Akzo Nobel Nv | Diphenylmethane piperidine derivatives pharmaceutical compositions containing them and a method for their preparation |
| JPH0977742A (ja) | 1995-09-12 | 1997-03-25 | Kyorin Pharmaceut Co Ltd | 新規なベンズアミド誘導体 |
| ZA9610738B (en) | 1995-12-22 | 1997-06-24 | Warner Lambert Co | Subtype selective nmda receptor ligands and the use thereof |
| JP2001507673A (ja) | 1996-10-28 | 2001-06-12 | シェーリング コーポレイション | ニューロキニンアンタゴニストとしての置換アリールアルキルアミン |
| US6124319A (en) * | 1997-01-21 | 2000-09-26 | Merck & Co., Inc. | 3,3-disubstituted piperidines as modulators of chemokine receptor activity |
| CA2296314A1 (en) | 1997-07-25 | 1999-02-04 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| IL125658A0 (en) | 1997-08-18 | 1999-04-11 | Hoffmann La Roche | Ccr-3 receptor antagonists |
| US6166037A (en) * | 1997-08-28 | 2000-12-26 | Merck & Co., Inc. | Pyrrolidine and piperidine modulators of chemokine receptor activity |
| US6140349A (en) * | 1998-02-02 | 2000-10-31 | Merck & Co., Inc. | Cyclic amine modulators of chemokine receptor activity |
| GB9919776D0 (en) * | 1998-08-31 | 1999-10-27 | Zeneca Ltd | Compoujnds |
| ES2230899T3 (es) * | 1998-11-17 | 2005-05-01 | F. Hoffmann-La Roche Ag | Antagonistas iii receptores de 4-aroil-piperidin-ccr-3. |
| JP3421323B2 (ja) | 1998-11-20 | 2003-06-30 | エフ．ホフマン−ラ ロシュ アーゲー | ピペリジンｃｃｒ−３受容体拮抗薬 |
| ATE271032T1 (de) | 1998-11-25 | 2004-07-15 | Gene Therapy Systems Inc | Amphiphile polyamin verbindungen |
| US6369112B1 (en) * | 1998-12-15 | 2002-04-09 | Bausch & Lomb Incorporated | Treatment of contact lenses with aqueous solution comprising a biguanide disinfectant stabilized by tyloxapol |
| US6331541B1 (en) * | 1998-12-18 | 2001-12-18 | Soo S. Ko | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6605623B1 (en) * | 1998-12-18 | 2003-08-12 | Bristol-Myers Squibb Pharma Co. | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6492400B1 (en) | 1998-12-18 | 2002-12-10 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| US6486180B1 (en) | 1998-12-18 | 2002-11-26 | Bristol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| CA2350730A1 (en) | 1998-12-18 | 2000-06-22 | George V. Delucca | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| DE69926806D1 (de) | 1998-12-18 | 2005-09-22 | Bristol Myers Squibb Pharma Co | N-ureidoalkylpiperidine als modulatoren der aktivität der chemokinrezeptoren |
| WO2000035449A1 (en) | 1998-12-18 | 2000-06-22 | Du Pont Pharmaceuticals Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| AU3386400A (en) * | 1999-03-02 | 2000-09-21 | Merck & Co., Inc. | 3-alkyl substituted pyrrolidine modulators of chemokine receptor activity |
| BR0009338A (pt) * | 1999-03-26 | 2001-12-26 | Astrazeneca Ab | Composto, processo para a preparação do mesmo,composição farmacêutica, processo para apreparação da mesma, uso de um composto, e,método de tratamento de uma doençainflamatória em um paciente sofrendo ou em riscode dita doença |
| US6358979B1 (en) * | 1999-06-11 | 2002-03-19 | Merck & Co., Inc. | N-cyclopentyl modulators of chemokine receptor activity |
| SE9902551D0 (sv) * | 1999-07-02 | 1999-07-02 | Astra Pharma Prod | Novel compounds |
| SE9902765D0 (sv) * | 1999-07-21 | 1999-07-21 | Astra Pharma Prod | Novel compounds |
| CO5300399A1 (es) | 2000-02-25 | 2003-07-31 | Astrazeneca Ab | Heterocicliocs que contienen nitrogeno, proceso para su preparacion y composiciones farmaceuticas que los contienen |
| AR033517A1 (es) | 2000-04-08 | 2003-12-26 | Astrazeneca Ab | Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos |
| CA2413274A1 (en) | 2000-06-21 | 2001-12-27 | George V. Delucca | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| JP2004516238A (ja) | 2000-06-21 | 2004-06-03 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | ケモカイン受容体活性調節剤としてのｎ−ウレイドアルキル−ピペリジン |
| JP2004517805A (ja) * | 2000-06-30 | 2004-06-17 | ブリストル−マイヤーズ・スクイブ・ファーマ・カンパニー | ケモカイン受容体活性調節剤としてのｎ−ウレイドヘテロシクロアルキル−ピペリジン |
| GB0021670D0 (en) | 2000-09-04 | 2000-10-18 | Astrazeneca Ab | Chemical compounds |
| US6855553B1 (en) | 2000-10-02 | 2005-02-15 | 3M Innovative Properties Company | Sample processing apparatus, methods and systems |
| WO2002030899A1 (en) | 2000-10-09 | 2002-04-18 | Novartis Ag | N-(4-aryloxypiperidin-1-ylalkyl) cinnamic amides as ccr3 receptor antagonists |
| MXPA03004652A (es) | 2000-12-21 | 2003-09-05 | Warner Lambert Co | Derivados de piperidina como antagonistas selectivos de subtipo de n-metil-d-aspartato. |
| SE0100087L (sv) * | 2001-01-12 | 2002-06-18 | Volvo Lastvagnar Ab | Tätningslist samt komponent innefattande en första och en andra del samt en tätningslist |
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| GB0117899D0 (en) | 2001-07-23 | 2001-09-12 | Astrazeneca Ab | Chemical compounds |
| TW200303304A (en) | 2002-02-18 | 2003-09-01 | Astrazeneca Ab | Chemical compounds |
| AU2003215024B2 (en) | 2002-03-26 | 2008-02-21 | Merck Sharp & Dohme Corp. | Spirocyclic amides as cannabinoid receptor modulators |
| SE0400208D0 (sv) | 2004-02-02 | 2004-02-02 | Astrazeneca Ab | Chemical compounds |
| TW200812582A (en) | 2006-04-06 | 2008-03-16 | Astrazeneca Ab | Medicaments |
-
2003
- 2003-02-07 TW TW092102511A patent/TW200303304A/zh unknown
- 2003-02-17 NZ NZ534296A patent/NZ534296A/en not_active IP Right Cessation
- 2003-02-17 JP JP2003567874A patent/JP4435571B2/ja not_active Expired - Fee Related
- 2003-02-17 AT AT03705600T patent/ATE480518T1/de not_active IP Right Cessation
- 2003-02-17 DE DE60334074T patent/DE60334074D1/de not_active Expired - Lifetime
- 2003-02-17 SG SG200605606-3A patent/SG149695A1/en unknown
- 2003-02-17 CA CA002472822A patent/CA2472822A1/en not_active Abandoned
- 2003-02-17 CN CNB038041308A patent/CN100352807C/zh not_active Expired - Fee Related
- 2003-02-17 AU AU2003206554A patent/AU2003206554B2/en not_active Ceased
- 2003-02-17 EP EP03705600A patent/EP1478624B1/en not_active Expired - Lifetime
- 2003-02-17 US US10/504,936 patent/US7709500B2/en not_active Expired - Fee Related
- 2003-02-17 PL PL03372538A patent/PL372538A1/xx not_active Application Discontinuation
- 2003-02-17 BR BR0307477-3A patent/BR0307477A/pt not_active IP Right Cessation
- 2003-02-17 WO PCT/SE2003/000258 patent/WO2003068743A1/en not_active Ceased
- 2003-02-17 KR KR10-2004-7012756A patent/KR20040084920A/ko not_active Ceased
- 2003-02-17 RU RU2004122114/04A patent/RU2330019C2/ru not_active IP Right Cessation
- 2003-02-17 MX MXPA04007906A patent/MXPA04007906A/es active IP Right Grant
- 2003-02-18 AR ARP030100530A patent/AR038566A1/es not_active Application Discontinuation
-
2004
- 2004-08-03 IS IS7381A patent/IS7381A/is unknown
- 2004-08-12 CO CO04078830A patent/CO5611135A2/es not_active Application Discontinuation
- 2004-09-17 NO NO20043899A patent/NO20043899L/no not_active Application Discontinuation
-
2007
- 2007-12-20 RU RU2007146928/04A patent/RU2007146928A/ru not_active Application Discontinuation
-
2008
- 2008-10-30 IL IL195011A patent/IL195011A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005525341A5 (https=) | ||
| RU2004122114A (ru) | Химические соединения | |
| JP5261575B2 (ja) | 化学化合物 | |
| TWI400232B (zh) | 含氮雜環衍生物及以該含氮雜環衍生物為有效成分之藥劑 | |
| ES2354407T3 (es) | Heteroarilpiperidinas y piperazinas y su uso como antipsicóticos y analgésicos. | |
| JP6117430B2 (ja) | 選択的ヒストン脱アセチル化酵素抑制剤としての新規化合物およびこれを含む薬剤学的組成物 | |
| JP5689119B2 (ja) | ジヒドロピリミジン化合物及び合成方法、医薬組成物及びその使用 | |
| WO2004080966A1 (ja) | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 | |
| JP2020533347A5 (https=) | ||
| WO2007105637A1 (ja) | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 | |
| WO2003000660A1 (fr) | Derive de quinoleine et derive de quinoleine permettant d'inhiber l'auto-phosphorylation du recepteur des proliferateurs des hepatocytes, ainsi que des compositions medicinales contenant ce derive | |
| AU782191B2 (en) | Substituted 1-aminoalkyl-lactams and their use as muscarinic receptor antagonists | |
| JP2005533803A5 (https=) | ||
| JP7178375B2 (ja) | デュアルｍａｇｌ及びｆａａｈインヒビター | |
| ES2277098T3 (es) | Derivados de quinolina y aza-indol y su uso como ligandos para 5-ht6. | |
| CZ242590A3 (en) | Substituted n-(aryloxyalkyl)heteroarylpiperidines and -heteroarylpiperazines, process of their preparation intermediate used in the process, pharmaceutical preparation and use | |
| KR20150018788A (ko) | 혈전색전성 질환의 치료를 위한 인자 ｘｉａ 억제제로서 치환된 피롤리딘 | |
| JP2010100642A (ja) | キナゾリン化合物 | |
| TW202208351A (zh) | 作為組蛋白去乙醯酶6抑制劑之新穎化合物及包含其之醫藥組合物 | |
| KR100909953B1 (ko) | 항진균 활성을 갖는 트라이아졸 유도체, 이의 제조방법 및이를 함유하는 약학 조성물 | |
| JP2007519695A5 (https=) | ||
| BR112020027064A2 (pt) | derivados de quinazolina do tipo éter biarílico | |
| ES2563440T3 (es) | Compuestos de piperidina inhibidores de prostaglandina D sintasa | |
| KR20160133001A (ko) | Tnks1 및/또는 tnks2의 억제제로서의 아미도-치환된 아졸 화합물 | |
| AU616708B2 (en) | 4-heteropentacyclic-4-{n-(phenyl)amido}piperidine derivatives and pharmaceutical compositions and method employing such compounds |